Page 26 - பல்கலைக்கழகம் மருத்துவமனை பேசல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article ZUG, Switzerland, Feb. 11, 2021 /PRNewswire/  MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have already been synthesized by MindShift Compounds AG and related patent applications were filed by MindMed. MindMed plans to begin first-in-human Phase 1 clinical trials as early as Q1 2022 through its existing clinical trial platform for psychedelic and empathogenic compounds in Switzerland.

United statesMiri halperin wernliFelix lustenbergerHead of clinical developmentLiechti labUniversity hospital basel liechti labMedicine mindmed incMindshift compoundsUniversity hospital baselNamed presidentClinical developmentMind medicineMind medicine mindmed incஒன்றுபட்டது மாநிலங்களில்மீறி ஹால்பெரின் வெற்ணிலிதலை ஆஃப் மருத்துவ வளர்ச்சி